Cargando…

Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Detalles Bibliográficos
Autores principales:	Kalra, Sanjay, Sahay, Rakesh, Baruah, Manash P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125112/ https://www.ncbi.nlm.nih.gov/pubmed/27620898 http://dx.doi.org/10.1007/s40119-016-0070-6

Ejemplares similares

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay
Publicado: (2016)

Erratum to: Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
por: Kalra, Sanjay
Publicado: (2015)

Medication counselling with sodium glucose transporter 2 inhibitor therapy
por: Kalra, Sanjay, et al.
Publicado: (2014)

Sodium-glucose Cotransporter 2 Inhibitor Use: A Pharmaco-ergonomic Qualification Tool
por: Kalra, Sanjay, et al.
Publicado: (2017)

Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study
por: Baruah, Manash P, et al.
Publicado: (2019)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

Erratum: Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
Publicado: (2016)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Erratum to: Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
Publicado: (2021)

Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
por: Hwang, Jiwon, et al.
Publicado: (2020)

Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
por: Kalra, Sanjay, et al.
Publicado: (2018)

Erratum. Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes 2019;68:248–257
por: Alicic, Radica Z., et al.
Publicado: (2019)

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
por: Hendryx, Michael, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)

Exploring the Cardiovascular Benefits of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: Expanding Horizons Beyond Diabetes Management
por: Fatima, Aroob, et al.
Publicado: (2023)

Salutogenesis in Type 2 Diabetes Care: A Biopsychosocial Perspective
por: Kalra, Sanjay, et al.
Publicado: (2018)

Erratum to: Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Person centered care in the Second Diabetes Attitudes, Wishes and Needs (DAWN2) study: Inspiration from India
por: Kalra, Sanjay, et al.
Publicado: (2014)

Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
por: Kalra, Sanjay
Publicado: (2014)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism
por: Xie, Lingxiang, et al.
Publicado: (2022)

Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation
por: Sano, Motoaki
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
por: Pradhan, Akshyaya, et al.
Publicado: (2019)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?
por: Ujjawal, Aditi, et al.
Publicado: (2022)

Sodium-glucose cotransporter–2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2018)

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
por: Kalra, Sanjay, et al.
Publicado: (2016)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Yang, Fan, et al.
Publicado: (2020)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Correction to: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta‑analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jvlk0si15vm6tv5fmnqfig0pi0